From the helm: Proteomics International (ASX:PIQ), Dr. Richard Lipscombe, Managing Director
Description
In this episode of From the helm, Bell Financial Group’s Grady Wulff speaks with Proteomics International Laboratories (ASX: PIQ) CEO, Dr. Richard Lipscombe, about the company’s ground breaking work in predictive diagnostics and the global opportunity for its world-first blood tests.
In this video, Dr. Lipscombe covers:
· (0:47 ): An overview of PIQ and its FY26 goals
· (1:38 ): The significance of three world-first blood tests
· (5:26 ): The global addressable markets for these conditions
· (6:25 ): Clinical trial progress and commercialisation roadmap
· (8:14 ): How the diagnostic tests work and deliver value to patients
· (9:16 ): Commercialisation strategy across key regions
· (11:23 ): Additional assets in the PIQ pipeline
· (12:36 ): What investors can expect over the next 12 months
Note: This interview was recorded on 3 July 2025.
United States
